North America RFID in Pharmaceuticals Market Report Scope & Overview:

North America RFID in Pharmaceuticals Market was valued at USD 1.87 Billion in 2025 and is expected to reach USD 3.85 Billion by 2035, growing at a CAGR of 7.50% from 2026-2035.

The North America RFID in Pharmaceuticals Market is expanding as drug manufacturers and hospital pharmacies accelerate item-level tagging to meet U.S. Drug Supply Chain Security Act enforcement milestones and reduce counterfeit drug exposure across increasingly complex distribution networks. Growing adoption of sensor-enabled tags is extending traceability into cold-chain condition monitoring for temperature-sensitive biologics, while point-of-manufacture tagging is easing the labeling workload previously carried by hospital pharmacy staff nationwide. Leading tag and reader suppliers continue to expand chipless and sterilization-ready product lines suited to vials, syringes, and other harsh-environment pharmaceutical packaging formats. Rising integration between RFID infrastructure and cloud-based EPCIS analytics platforms is further strengthening end-to-end visibility across the region’s pharmaceutical supply chain.

⮞In 2026, Zebra Technologies and Texas Children’s Hospital reported USD 14 million in annual medication cost savings from an RFID deployment.

US RFID in Pharmaceuticals Market Outlook

US RFID in Pharmaceuticals Market was valued at USD 1.66 Billion in 2025 and is expected to reach USD 3.39 Billion by 2035, growing at a CAGR of 7.40% from 2026-2035.

The US RFID in Pharmaceuticals Market is advancing as drug manufacturers and large pharmacy chains expand item-level tagging to satisfy Drug Supply Chain Security Act verification requirements and reduce diversion risk across increasingly complex distribution networks nationwide. Zebra Technologies’ deployment with Texas Children’s Hospital, which reported USD 14 million in annual medication cost savings, is reinforcing hospital pharmacy confidence in RFID-driven inventory accuracy programs across the country. Growing biologics and specialty drug manufacturing is widening demand for sensor-enabled tags capable of continuous cold-chain condition monitoring from production through last-mile delivery nationwide. Continued investment by tag, reader, and middleware suppliers in sterilization-compatible and chipless product lines is further broadening adoption across vials, syringes, and other sensitive packaging formats.

With the DSCSA stabilization window having closed on May 27, 2026, additional U.S. drug manufacturers are expected to move toward full item-level RFID verification as enforcement activity steps up nationwide.

North America RFID in Pharmaceuticals Market Segment Analysis

• By Component, RFID Tags dominate the North America RFID in Pharmaceuticals Market with 46.20% share in 2025; RFID Middleware is expected to grow at the fastest CAGR of 9.80% from 2026–2035.

• By Type, Chipped RFID dominates the North America RFID in Pharmaceuticals Market with 72.50% share in 2025; Chipless RFID is expected to grow at the fastest CAGR of 9.90% from 2026–2035.

• By Application, Drug Tracing & Authentication dominates the North America RFID in Pharmaceuticals Market with 53.10% share in 2025; Drug Quality & Condition Monitoring is expected to grow at the fastest CAGR of 10.30% from 2026–2035.

• By End User, Drug Manufacturers dominate the North America RFID in Pharmaceuticals Market with 49.20% share in 2025; Retail & E-Pharmacies are expected to grow at the fastest CAGR of 10.40% from 2026–2035.

By Component, RFID Tags Dominate the North America RFID in Pharmaceuticals Market, RFID Middleware Grows Fastest

RFID tags retained the largest component share across North America in 2025, supported by their low unit cost, straightforward integration into existing packaging lines, and mandatory status under emerging item-level serialization requirements for prescription drugs across the United States and Canada. Leading suppliers including Avery Dennison, CCL Industries, and Tageos have scaled high-volume inlay production to meet surging demand from drug manufacturers racing to satisfy Drug Supply Chain Security Act verification deadlines. Continued cost declines in chip-based and chipless tag manufacturing are reinforcing tags as the dominant revenue contributor across nearly every pharmaceutical packaging format even as middleware and software categories expand at a faster underlying rate through the forecast window.

RFID middleware is forecast to grow fastest through 2035 as drug manufacturers and distributors scale item-level verification programs that require reliable data capture, filtering, and transmission between readers and enterprise track-and-trace systems. Growing integration between on-site RFID infrastructure and cloud-based EPCIS analytics platforms is converting latent middleware demand into sustained software licensing and service growth faster than any other component category across the region. Expanding hospital and pharmacy chain deployments, each requiring tailored middleware configuration, are further reinforcing this growth pattern through the remainder of the 2026-2035 forecast period as integration requirements become more standardized.

By Type, Chipped RFID Dominates the North America RFID in Pharmaceuticals Market, Chipless RFID Grows Fastest

Chipped RFID tags remain the dominant type across North America given their established read-range performance, mature supplier ecosystem, and broad compatibility with existing pharmaceutical serialization and track-and-trace infrastructure built up over more than a decade. NXP Semiconductors and Impinj continue to supply the chip platforms underpinning most drug manufacturer and distributor deployments, reinforcing chipped RFID as the default technology choice across nearly every application category in the region. This structural position is expected to persist through the remainder of the forecast period even as chipless alternatives gain traction in cost-sensitive, high-volume tagging use cases across the broader pharmaceutical packaging landscape.

Chipless RFID is growing fastest as suppliers including Avery Dennison introduce sterilization-compatible inlay portfolios suited to vials, syringes, and other harsh-environment items where chip-based tags face cost or durability constraints. Falling production costs for printed and chipless formats are converting latent demand among smaller drug manufacturers and packaging converters into sustained volume growth faster than any other type category across the region. Continued expansion of chipless tag applications into blister packs and secondary packaging is expected to further reinforce this above-average growth trajectory through the remainder of the 2026-2035 forecast window as adoption broadens.

By Application, Drug Tracing & Authentication Dominates the North America RFID in Pharmaceuticals Market, Drug Quality & Condition Monitoring Grows Fastest

Drug tracing and authentication remains the largest application given direct regulatory pressure from the Drug Supply Chain Security Act, which requires manufacturers and distributors to maintain verifiable chain-of-custody records at the item level across the pharmaceutical distribution network. Established serialization infrastructure built by major drug manufacturers over the past decade continues to anchor this application as the dominant revenue contributor across nearly every RFID deployment in the region. With enforcement activity stepping up now that the DSCSA stabilization window has closed, tracing and authentication is expected to remain the leading driver of tag and reader purchasing decisions for the balance of the forecast period.

Drug quality and condition monitoring is set to post the fastest growth as biologics and other temperature-sensitive therapies drive demand for sensor-enabled tags capable of continuous cold-chain tracking from manufacturing through last-mile delivery. Growing biologics manufacturing investment across the United States and Canada is accelerating adoption of condition-monitoring RFID among drug manufacturers seeking to reduce spoilage-related losses and regulatory exposure. Rising integration of sensor data with cloud analytics platforms is expected to further reinforce this application’s above-average growth trajectory through the remainder of the 2026-2035 forecast window as biologics volumes continue expanding.

By End User, Drug Manufacturers Dominate the North America RFID in Pharmaceuticals Market, Retail & E-Pharmacies Grow Fastest

Drug manufacturers remain the largest end user given their direct regulatory obligation to serialize and verify products at the point of manufacture under the Drug Supply Chain Security Act across the United States and Canada. Point-of-manufacture tagging programs adopted by major pharmaceutical producers continue to anchor this end-user category as the dominant revenue contributor across nearly every RFID component and application in the region. Established supplier relationships between tag, reader, and middleware vendors and large drug manufacturers are expected to keep this group the primary purchaser of RFID infrastructure through the remainder of the forecast period as enforcement intensifies.

Retail and e-pharmacies are growing fastest as online prescription fulfillment expands and chains seek RFID-enabled inventory accuracy and anti-diversion controls across increasingly distributed fulfillment networks across the United States and Canada. Zebra Technologies’ hospital pharmacy deployment results are encouraging similar retail and e-pharmacy adoption as chains look to replicate comparable inventory and cost-saving outcomes region-wide. Growing consumer reliance on online pharmacy ordering is expected to further reinforce this end user’s above-average growth trajectory through the remainder of the 2026-2035 forecast period as digital fulfillment volumes continue to climb across the region.

Regional Analysis

US RFID in Pharmaceuticals Market Insights

The U.S. dominated the North America RFID in Pharmaceuticals Market with the highest revenue share of about 88.90% in 2025, supported by the scale of its pharmaceutical manufacturing base, direct regulatory pressure from the Drug Supply Chain Security Act, and the concentration of major tag, reader, and middleware suppliers headquartered in the country. Deployment results such as Zebra Technologies’ reported USD 14 million in annual savings for Texas Children’s Hospital continue to reinforce hospital and retail pharmacy confidence in RFID-driven inventory programs nationwide. With enforcement activity rising since the DSCSA stabilization window closed, the United States is set to stay the primary revenue engine for the regional market for the remainder of the decade.

Continued expansion of item-level serialization programs, growing biologics manufacturing investment, and sustained hospital and retail pharmacy modernization reinforce U.S. dominance within North America across nearly every component and application category. Ongoing supplier investment in sterilization-compatible and chipless tag portfolios is also easing adoption barriers that previously limited RFID use on vials and syringes, supporting continued volume growth through 2035. This structural position is expected to continue shaping purchasing and deployment decisions across the market through the remainder of the forecast period as enforcement and modernization efforts proceed in parallel nationwide.

Canada RFID in Pharmaceuticals Market Insights

The Canada segment is expected to grow at the fastest CAGR of about 8.27% from 2026–2035, facilitated by growing cross-border integration with U.S. serialization and track-and-trace infrastructure and rising investment by Canadian drug manufacturers and distributors in item-level verification capability. Growing federal attention to pharmaceutical supply chain security is reinforcing Canada’s above-regional growth trajectory as hospital networks and retail pharmacy chains begin adopting RFID-enabled inventory and anti-diversion programs. This dynamic is expected to persist through the remainder of the 2026-2035 forecast window as Canadian manufacturers continue aligning deployment practices with U.S. regulatory requirements.

Moreover, continued investment by major RFID suppliers in Canadian distribution and technical support infrastructure, combined with growing hospital network interest in point-of-manufacture tagging, is supporting faster-than-average volume growth across the country through the forecast period. Expanding biologics and specialty drug manufacturing tied to Ontario and Quebec’s pharmaceutical production base is expected to further reinforce Canada’s above-regional growth rate through 2035. Continued cross-border supplier coordination is expected to reinforce this pattern through the remainder of the decade as volumes and deployment practices continue to converge with the broader North American market.

Market Dynamics

Growth Drivers: DSCSA enforcement and expanding biologics manufacturing are increasing demand for item-level and cold-chain RFID tagging.

Continued enforcement of Drug Supply Chain Security Act serialization milestones is pushing drug manufacturers and distributors across the United States and Canada to accelerate item-level RFID verification investment ahead of stabilization-period deadlines. Growing biologics and specialty drug manufacturing is widening demand for sensor-enabled tags capable of continuous cold-chain condition monitoring from production through last-mile pharmacy delivery. Falling tag production costs and expanding chipless product portfolios are further easing adoption among smaller manufacturers and packaging converters previously deterred by cost. Hospital pharmacy automation programs, reinforced by reported cost-saving outcomes at deployments such as Texas Children’s Hospital, are expected to sustain this trajectory through the remainder of the forecast period.

Restraints: High integration costs and RF performance limitations near metal and liquids continue to complicate deployment decisions.

High integration and validation costs continue to complicate RFID adoption decisions for smaller drug manufacturers and distributors across North America, particularly where legacy packaging lines require significant retrofitting to accommodate tagging equipment. Reduced RF read performance near metal shelving and liquid-filled containers remains a persistent technical constraint for pharmacy and distribution-center deployments, requiring careful site-specific engineering. Data security and standards fragmentation across different reader and middleware platforms add further complexity to enterprise-wide rollout decisions. The fact that the Drug Supply Chain Security Act does not explicitly mandate RFID technology continues to leave some manufacturers evaluating alternative serialization approaches alongside RFID.

Opportunities: Automated bulk verification and sensor-enabled cold-chain monitoring create substantial long-term growth potential.

Expanding demand for automated bulk verification at distribution centers and returns-processing points is opening substantial new RFID deployment opportunities well beyond traditional point-of-manufacture tagging across North America. Growing adoption of sensor-enabled tags capable of continuous temperature and condition monitoring is creating new product lines tailored to biologics, vaccines, and other temperature-sensitive therapies moving through increasingly complex distribution networks. Continued supplier investment in sterilization-compatible and chipless formats is also expected to broaden RFID use into vials, syringes, and other historically difficult-to-tag packaging formats, supporting more sustainable long-term category growth across the region through the remainder of the forecast period.

North America RFID in Pharmaceuticals Market key players are:

• Avery Dennison Corporation

• Zebra Technologies Corporation

• Impinj, Inc.

• CCL Industries Inc. (Smartrac)

• Fresenius Kabi AG

• Checkpoint Systems, Inc.

• NXP Semiconductors N.V.

• SATO Holdings Corporation

• Schreiner MediPharm

• Tageos SAS

• GAO RFID Inc.

• Invengo Technology Corp.

• Honeywell International Inc.

• Siemens AG

• Bluesight, Inc.

• Paragon ID Plc

• Turck Vilant Systems

• p-Chip Corporation

• Confidex Ltd.

• Mojix, Inc.

North America RFID in Pharmaceuticals Market Report Scope